Content
Hosted by therapist Amy Morin, LCSW, this episode of The Verywell Mind Podcast, featuring psychologist Brian Pilecki, shares how psychedelics can be used to treat emotional pain. However, research suggests that there is a low risk for physical dependence and abuse. In one study, researchers recommended scheduling the substance no more restrictively than a Schedule IV. Despite interest in the therapeutic potential of psilocybin, it remains a Schedule I substance and illegal for use. Various cultures and religious traditions have long utilized psychedelic substances as part of traditional medicine and spiritual rituals. While there has been a recent uptick in interest and research on the therapeutic uses for psilocybin and other psychedelics, their use for medicinal and spiritual purposes is nothing new.
Neuroplasticity: How to rewire your brain
Often known for a hallucinogenic effect, many people have started using psilocybin as a mental health and pain treatment. A new study published in the Annals of Internal Medicine examines the increase in psilocybin consumption along with the benefits https://ecosoberhouse.com/article/how-to-lower-weed-tolerance/ and risks of taking it. Participants were randomly assigned to receive either a synthetic form of psilocybin (51 people) or niacin, the control condition (53).
Uses and benefits of psychedelic therapy
Even patients who find some form of relief from the usual prescribed antidepressants need frequent doses, causing unpleasant side-effects, and these drugs often lose their effectiveness after several years of treatment. What we really need, argue many psychiatrists and mental health professionals, is a paradigm shift in the way we treat depression. Like all psychedelics, psilocybin is currently classified as a Schedule I illegal substance, not yet having demonstrated sufficient safety and efficacy in controlled clinical trials. Therefore, outside of state-level wellness models or underground settings, the drug is not yet available for the treatment of depression.
Faculty Biostatistics & Epidemiology – Quantitative Health Sciences, Cleveland Clinic
Synthetic forms of psilocybin have been studied for safety and efficacy in treating depression. The subjects who received 25 mg experienced significantly lower depression scores at three weeks vs baseline, in many cases, the benefits were sustained at three months. Some of the most compelling results for MDMA as a treatment for mental illness have come from clinical trials involving people with PTSD. A randomized, placebo-controlled trial published in 2023 studied 104 participants with moderate or severe PTSD for three treatment sessions over 18 weeks. It found that 71 percent of those who received MDMA-assisted therapy no longer met common diagnostic criteria for PTSD at the end of treatment compared with 48 percent of those who received a placebo in conjunction with therapy.
Psilocybin: Potential Psychedelic Treatment for Depression
Instead, it produces feelings of good mood, euphoria, love and social connectedness. There is preliminary evidence that in controlled clinical settings, supported by psychotherapy, it is what is alcoholism a safe and effective treatment for PTSD. Psychedelics are still highly regulated by federal laws that prohibit their manufacture, distribution and use.
In addition to the suffering depression causes, it often leads to major life disruptions, such as missed work, strained relationships, and substance use disorders. An earlier study by Dr. Carhart-Harris looked at the changes within the brain caused by psilocybin, in ordinary non-depressed people. The researchers found that psilocybin disrupts the DMN, a part of the brain that ties together our normal consciousness. By disrupting the DMN, psilocybin releases consciousness from its stringent control mechanisms.
Afterwards, the therapist will work with the individual to help them integrate their psychedelic session. The goal is to help the person process and find meaning in what they have just experienced. One issue is that we aren’t sure whether findings might be due to a placebo effect, which occurs when a treatment works because people expect it to work. Psilocybin is a hallucinogen that changes the brain’s response to a chemical called serotonin. When broken down by the liver (into “psilocin”), it causes an altered state of consciousness and perception in users. This article is part of AP’s Be Well coverage, focusing on wellness, fitness, diet and mental health.
A large team of researchers across 11 sites in the US recruited 104 participants with mild to moderate depression. They excluded people with a history of psychosis or mania, more than a mild current substance use problem, and active suicidal intent. Those on medication for depression gradually tapered off the drug before the treatment phase of the study. Strictly speaking, a psychedelic is a “mind-manifesting” drug — a definition that’s open to interpretation. They tend to produce perceptual distortions or hallucinations by activating 5-HT2A receptors. One of the hallmarks of depression is the atrophy of neurons in the prefrontal cortex — a region of the brain that controls anxiety and regulates mood among other things.
- People take psychedelic drugs recreationally in ways that include smoking, snorting, injecting, and drinking them.
- “For example, in depressed adults, we see abnormally increased amygdala, as well as ventral striatal and medial prefrontal cortex activity.
- Like ketamine, psychedelics have shown promise in the clinic for treating neuropsychiatric diseases.
- A 2020 systematic review looked at four studies of MDMA and five studies of ketamine for the treatment of trauma.
Participants were also less emotionally avoidant and their cognitive functioning got better. The improvement in their depressive symptoms correlated with changes to their brains, and these changes lasted until the study ended three weeks after the second psilocybin dose. No such changes were seen in the brains of those who received escitalopram, suggesting that psilocybin acts differently on the brain than SSRIs. The researchers provided preparatory sessions and a non-traditional environment, which might be difficult or costly to replicate in a non-research environment.
Meanwhile, psychedelics act on neural circuits, stimulating, suppressing, or modulating the activity of the networks that use serotonin. Approximately one-third of patients with MDD aren’t helped by existing therapies and are at high risk of developing treatment-resistant depression. TRD is generally defined as an inadequate response to two or more appropriate courses of approved medications. TRD has a significantly greater impact on individuals compared to MDD, leading to residual symptoms, poorer quality of life, increased comorbidities, higher mortality, and an increased risk of suicide.
- The authors caution that while these findings are encouraging, patients with depression should not attempt to self-medicate with psilocybin.
- Mounting evidence is suggesting that hallucinogenic drugs can be effective therapies for treatment-resistant depression and anxiety.
- Compass is headquartered in London, UK, with offices in New York and San Francisco in the US.
- A 2020 review reported on 24 prior studies on psychedelic drugs to treat anxiety symptoms.
- This suggests mystical experiences may play a role in the mental health benefits of psychedelics.
In many cases, healthcare professionals recommend this form of therapy for people whose symptoms have not responded well to standard medications or therapies. People with a history of mania, severe heart disease, or psychotic disorders such as schizophrenia should not be considered for psychedelic therapy, Johnson says. More surprising still is that, according to the study, more adults used psilocybin in 2023 than drugs like LSD, methamphetamine, cocaine, and illegal opioids. The study found that the rate of use increased by 44 percent in young adults (18 to 26) and by 188 percent in adults over 30 within the last year. Along with that, poison control centers saw an increase in calls concerning psilocybin poisoning. Taken together, these brain changes and subjective experiences “can allow people to heal in ways that traditional talk therapy and other existing pharmacological solutions” aren’t able to, according to Zemon.
Hallucinogenic mushrooms have shown promise for their medical benefits, but we are only now beginning to understand how they might help to treat depression. “People may call just to simply process their experience,” said project founder Josh White, who microdoses the plant iboga and LSD to “continue to deepen the insight about my life” that he gained in a full-blown psychedelic experience. One small study did find glimmers of an effect of small LSD doses on vigor and elation in people with mild depression when compared with a placebo. In one study involving people who microdose, participants didn’t know until afterward whether they had spent four weeks taking their usual microdose or placebos. Psychological measures improved after four weeks for everyone in the study, regardless of whether they were taking microdoses or empty capsules. While depression gets the mushroom treatment, generalized anxiety disorder is being put, you might say, to the acid test.
Psychedelics, by disrupting the DMN and opening up consciousness to new ways of thinking, could be that treatment. The patient’s depressive symptoms were measured before, one week after, and three months after the trial using an approved scoring system. All the patients showed improved depression scores after a week, and seven patients retained this improvement after three months. Our studies on neurons grown in dishes, as well as experiments performed using fruit flies and rodents, have demonstrated that several psychoplastogens, including psychedelics and ketamine, encourage neurons to grow more branches and spines. It seems that all of these compounds work by activating mTOR — a key protein involved in cell growth. Psychedelic-assisted therapy has shown some promise in treating depression, especially treatment-resistant depression.
